Eli Lilly faces fresh legal scrutiny as Parker Waichman files multiple lawsuits alleging a link between the blockbuster drug Mounjaro and cases of NAION vision loss.
Eli Lilly faces potential legal headwinds as law firm Parker Waichman has initiated multiple lawsuits alleging that patients developed non-arteritic anterior ischemic optic neuropathy (NAION) following the use of Mounjaro. These filings represent a direct challenge to the safety profile of one of the company's flagship GLP-1 medications, potentially impacting investor sentiment and future liability costs.
The lawsuits allege that patients developed non-arteritic anterior ischemic optic neuropathy (NAION) after taking Mounjaro.
The national law firm Parker Waichman has filed the multiple lawsuits mentioned in the report.
Law firm Parker Waichman has initiated multiple lawsuits against Eli Lilly, alleging that patients developed non-arteritic anterior ischemic optic neuropathy (NAION) after using the GLP-1 medication Mounjaro. These legal filings introduce a new layer of litigation risk for the pharmaceutical giant as it navigates the competitive weight-loss drug market.
The lawsuits allege that patients developed non-arteritic anterior ischemic optic neuropathy (NAION), a form of vision loss, after taking the GLP-1 medication Mounjaro.